Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L

Anticancer Research

Volumn 18, Issue 3 C, 1998, Pages 2173-2180

  Thomssen, Christoph ^a   Oppelt, Peter ^b   Jänicke, Fritz ^a   Ulm, Kurt ^c   Harbeck, Nadia ^d   Höfler, Heinz ^e   Kuhn, Walther ^d   Graeff, Henner ^d   Schmitt, Manfred ^d,e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; Cathepsin L; PAI 1; Prognosis; Protease; Tumor invasion

Indexed keywords

CATHEPSIN L; PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROID RECEPTOR; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, STEROID; RISK FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031880339     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Danø K, Andreasen PA. Grøndahl-Hansen J, Kristensen P, Nielsen LS, and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
2. Schmitt M, Jänicke F, Graeff H: Tumor-associated proteases. Fibrinolysis Suppl 4: 3-26, 1992.
3. Schmitt M, Wilhelm O, Jänicke F, Magdolen V, Reuning U, Ohi H, Moniwa N, Kobayashi H, Weidle U, Graeff H: Urokinase-type plasminogen activator (uPA) and its receptor (CD87). A new target in tumor invasion and metastasis. J Obstet Gynaecol 21: 151-165, 1995.
4. Jänicke F, Schmitt M, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 334: 1049, 1989.
5. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78, 1990.
6. Jänicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and the tissue-type plasminogen activators and of their inhibitor PAI-1 in breast cancer. Sem Thrombosis Hemost 17: 303-312, 1991.
7. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fenelly JJ, Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-689, 1990.
8. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ: Urokinase plasminogen activator and prognosis in breast cancer. Lancet 335: 108, 1990.
9. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Brontenbal M, Jänicke F, Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
10. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, Le Doussal V, Tubiana-Hulin M, Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272, 1993.
11. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 55: 2513-2521, 1992.
12. Duffy M, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 62: 531-533, 1988.
13. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993.
14. Foekens JA, Schmitt M, van Putten WLJ., Peter HA, Jänicke F, Klijn JMG: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658, 1994.
15. Fernö M, Bendahl P, Borg A, Brundell J, Hirschberg L, Olsson H, Killander D: Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a iuminometric immunoassay. Eur J Cancer 32A: 793-801, 1996.
16. Jänicke F, Thomssen C, Pache L, Schmitt M, Graeff H: Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Schmitt M, Graeff H, Kindermann G, editors. Prospects in diagnosis and treatment of cancer. International Congress Series 1050, Excerpta Medica. Amsterdam: Elsevier, pp. 207-218, 1994.
17. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530, 1994.
18. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, Jänicke F, Graeff H: Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clin Cancer Research 1: 741-746, 1995.
19. Nekarda H, Siewert JR, Schmitt M, Ulm K: Tumor-associated proteolytic factors uPA and PAI-1and survival in totally resected gastric cancer. Lancet 343: 117, 1994.
20. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
21. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34: 187-200, 1972.
22. Stetler-Stevenson WG, Liotta LA, Kleiner DE: Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. Faseb J 7: 1434-1441, 1993.
23. Sloane BF: Cathepsin B and cystatins: evidence for a role in cancer progression. Seminars in Cancer Biology 1: 137-152, 1990.
24. Lah TT, Calaf G, Kalman E, Shinde BG, Russo J, Jarosz D, ZabreckyJ, Somers R, Daskal I: Cathepsins D, B and L in breast carcinoma and in transformed human breast epithelial cells (HBEC). Biol Chem Hoppe-Seyler 376: 357-363, 1995.
25. Liu G, Shuman MA, Cohen RL: Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60: 501-506, 1995.
26. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F, Graeff H: Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 76: 306-311, 1997.
27. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31.000 recurrences and 24.000 deaths among 75.000 women. Lancet 339: 1-15 + 71-85, 1992.
28. Chauhan SS, Goldstein LJ, Gottesmann MM: Expression of cathepsin L in human tumors. Cancer Res 51: 1478-1481, 1991.
29. Barrett AJ, Kirschke H: Cathepsin B, cathepsin H, cathepsin L. In: L. Lorand, editor. Methods in Enzymology. New York: Academic Press 80: 535-561, 1981
30. Yee C, Shiu RPC: Degradation of endothelial basement membrane by human breast cancer cell lines. Cancer Res 46: 1835-1839, 1986.
31. Trygvasson K: Extracellular matrix and its enzymatic degradation in tumor invasion (A review). In: Liotta, LA, editor. Influence of tumor development on the host. Dordrecht: Kluwer Academic Publishers, pp. 72-83, 1989.
32. Sloane BF, Cao L, Sameni M: Trafficking of cathepsin B in tumor cells. Proceed Am Assoc Cancer Res 34: 603, 1993.
33. Godbold GD, Chapman RL, Yeyeodu S, Erickson AH: Binding of procathepsin L to the lysosomal proenzyme receptor is altered in tumor cells. In: Matrisian LM. Sloane BF, editors. Proteases and protease inhibitors. AACR Special Conference. Panama City, FL, Abstract, 1996.
34. Troen BR, Gal S, Gottesman MM: Sequence and expression of the cDNA for MEP (major excreted protein), a transformation-regulated secreted cathepsin. Biochem J 246: 731-735, 1987.
35. Goretzki L, Schmitt M, Mann K, Calvete J, Chuchulowski N, Kramer M, Günzler WA, Jänicke F, Graeff H: Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 297: 112-118, 1992.
36. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H: Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401-409, 1994.
37. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907, 1994.
38. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW: Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow: A reference to early systemic disease in solid cancer. Nature Medicine 1: 1035-1039, 1995.
39. Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, van de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB, Verspaget HW: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071, 1994.
40. Pedersen H, Brunner N, Francis D, Osterlind K, Rχnne E, Hansen HH, Danø K, Grøndahl-Hansen J: Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675, 1994.
41. Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M, Grothe F: Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol 155: 858-862, 1996.
42. Kobayashi H, Fujishiro S, Terao T: Impact of urokinase type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539-6548, 1994.
43. Sier FM, Vloedgraven HJM, Ganesh S, Griffioen G, Quax PHA, Verheijen JH, Dooijeward G, Welvaart K, van de Velde CJH, Lamers CBHW, Verspaget HW: Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 107: 1449-1456, 1994.
44. Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H: Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator (uPA), its receptor (uPA-R) and inhibitors type-1 (PAJ-1) and type-2 (PAI-2). Cancer Research 55: 3958-3963, 1995.
45. Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Jänicke F, Nathrath W, Schmitt M, Graeff H, Höfler H: Prognostic impact of the proliferation associated factors Ki-67 and S-phase in node-negative breast cancer using MIB1 immunostaining and flowcytofluorometric S-phase determination. Br J Cancer 75: 1525-1533, 1997.